Study Stopped
not feasible
Myocardial Injury After Radical Nephrectomy
MANE
1 other identifier
observational
N/A
1 country
1
Brief Summary
Kidney removal for cancer (nephrectomy) is a major operation. People can develop heart complications during or after surgery, especially if they are older or already have heart disease. One form of heart damage is called myocardial injury (MINS). This can be detected with a simple and easily available blood test. Unlike a heart attack, MINS doesn't cause changes in the electrical tracing of the heart (ECG) and it typically doesn't cause symptoms like pain. However, it can lead to heart problems and a stroke after surgery. We do not know how many people having a nephrectomy develop MINS. It is important to know if people are at high risk of MINS to help decide future treatment. There are a few different ways of carrying out nephrectomy surgery. These can be traditional open surgery, keyhole surgery or robotic surgery. We know that MINS is more likely if there has been a lot of bleeding during the operation, but other factors are also important. Therefore, it's important to monitor the relationship between blood loss, rates of MINS and method of surgery. We aim to recruit 120 participants undergoing nephrectomy to see how many develop MINS and to compare blood loss between different ways of surgery. Patients will be asked to consent to have blood tests on the day of and the day after surgery. This test will be added to routine hospital blood tests (and so no extra samples are needed). These results will show how many patients are diagnosed with MINS after nephrectomy. Around 90 days after the surgery, their quality of life and any further heart or breathing problems will also be recorded. We hope to identify the rates of and risk factors for MINS, so future patients can be spared this complication of surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 16, 2024
CompletedFirst Submitted
Initial submission to the registry
July 17, 2024
CompletedFirst Posted
Study publicly available on registry
July 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedSeptember 9, 2025
January 1, 2025
12 months
July 17, 2024
September 2, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of patients undergoing radical nephrectomy with evidence of myocardial injury (MINS)
This will be defined as a raised troponin level \>99th percentile upper reference limit on any sample taken within 72 hours following the operation.
72 hours post surgery
Secondary Outcomes (4)
Occurrence of intraoperative and post-operative blood transfusion
72 hours post surgery
Number of days out of hospital
90 days post surgery
Rate of major adverse cardiac events (MACE)
90 days post surgery
Impact on quality of life, assessed by EQ-5D-5L questionnaire completed by patients
90 days post surgery
Study Arms (2)
Laparoscopic nephrectomy
Robotic nephrectomy
Eligibility Criteria
Surgery waiting lists will be screened by members of the research team at Sheffield Teaching Hospitals to identify patients that will be undergoing a radical nephrectomy for suspected renal cancer. The surgical approach will already have been decided before the study is introduced. Those eligible will be contacted via phone to discuss the study further.
You may qualify if:
- Adult patients (aged 18 and above)
- Undergoing a radical nephrectomy (either laparoscopic or robotic) for suspected renal cancer
- Stage \<T3a
- Can provide informed consent
You may not qualify if:
- Patients under 18
- Undergoing partial nephrectomy
- Undergoing radical nephrectomy not for suspected renal cancer
- Unable to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, S10 2JF, United Kingdom
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 17, 2024
First Posted
July 23, 2024
Study Start
April 16, 2024
Primary Completion
March 31, 2025
Study Completion
June 1, 2025
Last Updated
September 9, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share